Idiopathic pulmonary fibrosis and sleep disorders: No longer strangers in the night

Sophia Schiza, Charalampos Mermigkis, George A. Margaritopoulos, Zoi Daniil, Sergio Harari, Venerino Poletti, Elizabetta A. Renzoni, Olga Torre, Dina Visca, Isolde Bouloukaki, George Sourvinos, Katerina M. Antoniou

Research output: Contribution to journalArticlepeer-review

Abstract

The prevalence of obstructive sleep apnoea (OSA) is continuously increasing in patients with idiopathic pulmonary fibrosis (IPF) and, for the first time, the recent IPF guidelines recognise OSA as an important associated comorbidity that can affect patient’s survival. Thus, it becomes conceivable that clinicians should refer patients with newly diagnosed IPF to sleep centres for the diagnosis and treatment of OSA as well as for addressing issues regarding the reduced compliance of patients with continuous positive airway pressure therapy. The discovery of biomarkers common to both disorders may help early diagnosis, institution of the most appropriate treatment and follow-up of patients. Better understanding of epigenetic changes may provide useful information about pathogenesis and, possibly, development of new drugs for a dismal disease like IPF.

Original languageEnglish
Pages (from-to)327-339
Number of pages13
JournalEuropean Respiratory Review
Volume24
Issue number136
DOIs
Publication statusPublished - Jun 1 2015

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint Dive into the research topics of 'Idiopathic pulmonary fibrosis and sleep disorders: No longer strangers in the night'. Together they form a unique fingerprint.

Cite this